

RealRate

PHARMACEUTICAL 2020

Histogen Inc. Rank 65 of 358









RealRate

PHARMACEUTICAL 2020

Histogen Inc. Rank 65 of 358



The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 134% points. The greatest weakness of Histogen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 199%, being 163% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	21,606
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,640
Liabilities, Non-Current	0
Other Assets	221
Other Compr. Net Income	17
Other Expenses	0
Other Liabilities	0
Other Net Income	621
Other Revenues	21,717
Property and Equipment	0
Research and Development	23,527
Selling, General and Administrative Expense	10,196

Output Variable	Value in 1000 USD
Assets	21,827
Liabilities	1,640
Expenses	33,723
Revenues	21,717
Stockholders Equity	20,187
Net Income	-11,385
Comprehensive Net Income	-11,376
Economic Capital Ratio	199%

